traditional chemotherapy: alkylating agents

0.0(0)
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
Card Sorting

1/37

encourage image

There's no tags or description

Looks like no tags are added yet.

Study Analytics
Name
Mastery
Learn
Test
Matching
Spaced

No study sessions yet.

38 Terms

1
New cards

Primary chemotherapy

used for many hematologic cancers and advanced solid tumors for which no alternative treatment exists

curative in a small number or patients with advanced metastatic disease, palliative for many others

2
New cards

Neoadjuvant chemotherapy

for patients with localized diseases where other therapy such as surgery can be used

goal is to reduce size of tumor to increase effectiveness of surgery

3
New cards

Adjuvant chemotherapy

used for many patients alongside local treatments such as surgery or radiation

goal of reducing local and systemic recurrence

4
New cards

Log (1st order) kill hypothesis

chemo at a certain dose kills a constant fraction of tumor cells, rather than a constant number

5
New cards

Cell cycle-specific (CCS) drugs

kill cells in a specific phase of replication

6
New cards

Cell cycle-nonspecific (CCNS) drugs

kill cells in both resting and replicating phases

7
New cards

Glutathione

produced by cancer cells as a resistance mechanism

traps chemo-drugs to prevent their activity

8
New cards

Alkylating agents

cyclophosphamide, carmustine, platinum analogs, mitomycin

9
New cards

Anthracyclines

doxorubicin, daunorubicin, mitoxantrone

10
New cards

Cell cycle-nonspecific (CCNS) drugs

alkylating agents, anthracyclines

11
New cards

Alkylating agents

form reactive molecular species affecting nucleophilic groups on DNA bases, particularly N-7 position on guanine

12
New cards

Alkylating agents

myelosuppression, N/V/D, mucosistis, hair loss, increased risk of secondary malignancies

13
New cards

Cyclophosphamide

metabolized to form cytotoxic metabolites

14
New cards

Cyclophosphamide

high oral bioavailability, also given IV

used for leukemia, non-Hodgkin’s lymphoma, ovarian cancers, and neuroblastoma

15
New cards

Phosphoramide mustard

active metabolite of cyclophosphamide

16
New cards

Acrolein

inactive, toxic metabolite of phosphamides

17
New cards

Hemorrhagic cystitis

caused by build up of acrolein causing genitourinary bleeding

18
New cards

Chloroacetaldehyde

neurotoxic metabolite of phosphamides produced by CYP3A4

19
New cards

MESNA

given prophylactically to counteract acrolein toxicitiy

20
New cards

Neurotoxicity

risk factors: renal/hepatic dysfunction, low serum albumin, old age

21
New cards

Methylene blue

thought to reverse neurotoxicity by inhibiting MAO, which prevents formation of chloroacetaldehyde

22
New cards

Ifosfamide

makes extremely high amounds of acrolein

23
New cards

MESNA

given with high dose cyclophosphamide and all doses of ifosfamide

24
New cards

Melphalan

dose-limiting myelosuppression, mucositis (canker sores in entire mouth)

extremely hot feeling during infusion (give ice chips or cold blanket)

25
New cards

Melphalan

given orally or IV

used in stem cell transplant conditioning regiments

26
New cards

Mustard alkylators

myelosuppression, alopecia, GI toxicity, gonadal toxicity

27
New cards

Nitrosoureas (carmustine, lomustine), temozolamide (TMZ)

lipophilic drugs that require nonenzymatic decomposition to form active drugs

28
New cards

Temozolamide

orally administered

standard of care for high-grade gliomas

29
New cards

Nitrosoureas

delayed nadir of 42 days, administered q6w

30
New cards

Carmustine

administered IV or implanted intracranial wafer

ethanol used as IV vehicle

pulmonary toxicity (fibrosis)

31
New cards

Lomustine

administered orally

less risk of pulmonary toxicity (fibrosis)

32
New cards

Busulfan

misc alkylating agent

causes dose-limiting pancytopenia

must give with seizure prophylaxis (usually levetiracetam)

33
New cards

Mitomycin

misc alkylating agent, mostly used palliatively

causes dose limiting myelosuppression, especially thrombocytopenia and leukopenia

vesicant: can cause severe tissue necrosis

turns urine blue-green

34
New cards

Platinum analogs

cisplatin, carboplatin, oxaliplatin

35
New cards

Cisplatin

absolute max dose of 100 mg/m2 per cycle due to nephrotoxicity

also must hydrate with magnesium/potassium pre and post infusion

can also induce ototoxicity and neuropathy with dose accumulation

36
New cards

Carboplatin

dosed with Calvert formula

dose (mg) = target AUC (4-6) * (eGFR + 25)

eGFR capped at 125

37
New cards

Carboplatin

dose limiting myelosuppression, moderate emetogenic potential, hypersensitivity with exposure > 6 cycles

38
New cards

Oxaliplatin

dose limiting chronic peripheral neuropathy, myelosuppression, moderate emetogenic potential

extreme cold sensitivity that triggers neuropathy (reaching into freezer for a popsicle can trigger it)